FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications

Post Content

CHICAGO, Jan. 13, 2026 /PRNewswire/ — Aon plc (NYSE: AON), a leading global professional services firm, today released updated findings from its multi-year study of

Obesity now affects roughly 20% of U.S. children, according to the CDC, and families are searching for solutions that could include injectable weight loss drugs

Oral weight-loss drugs could account for a third or more of the overall GLP-1 market by 2030, a Novo Nordisk executive said, a larger percentage

Cornell University When Americans begin taking appetite-suppressing drugs like Ozempic and Wegovy, the changes extend well beyond the bathroom scale. According to new research, the…

Bariatric surgery and GLP-1 drugs are associated with reductions in fat mass and a shift in body composition toward a higher ratio of fat-free mass

Butyrate is a short-chain fatty acid (SCFA) produced in your gut when beneficial bacteria ferment dietary fiber, which your body cannot digest on its own.

At the start of a new year, when many people are reviewing their personal finances, income investors often look for promising dividend shares to add

Novo Nordisk CEO Mike Doustdar told Jim Cramer about developments in obesity treatment.

Post Content

Mike Doustdar, Novo Nordisk president and CEO, joins ‘Mad Money’ host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.

Mike Doustdar, Novo Nordisk president and CEO, joins ‘Mad Money’ host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.

Weight loss drugs have shown impressive short-term results, but new research suggests their benefits may be difficult to sustain once treatment ends. Stopping treatment with

Treatment of alcohol use disorder is shaping up to be another win for the GLP-1 weight-loss drugs. Medscape

One in eight Americans are taking a GLP-1 drug, a recent poll found

Novo Nordisk A/S’s obesity pill will allow it to tap into a massive population of patients that have not yet taken GLP-1s , the drugmaker’s

Novo Nordisk sees pills capturing over third of GLP-1 obesity market by 2030  Reuters

Nick Reiner’s weight gain set him on a murderous path, but it didn’t have to be that way … just ask Dr. Drew. The good

Pharma has much to learn from the surprising boom of telehealth sales of obesity drugs, Novo Nordisk’s CEO Mike Doustdar said at the Endpoints at

Pfizer CEO Albert Bourla told Bloomberg’s Katie Greifeld Pfizer is looking for ‘superior results’ while developing and testing further GLP-1 weight loss medications in a

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown promise in preclinical models of neurodegeneration, with emerging evidence suggesting these effects may be driven by modulation

> In my friend circle in Germany I don’t even know one single person on this stuff. Most people don’t announce when they’re taking a

Of all the television personalities on GLP-1s like Ozempic, Tom Brady doesn’t appear to be one of them. You don’t play in the NFL into

MONDAY, Jan. 12, 2026 — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for colorectal cancer (CRC) incidence compared with

While GLP-1s boast impressive weight loss results, making one mistake could result in the pounds coming right back on, according to new research.

Back in the 2010s, celebrating bodies of all sizes was the rage. People magazine featured plus-size model Tess Holliday on the cover after her 2013

The startup helps companies cover the high cost of GLP-1 drugs for employees

Jan 12 (Reuters) – Novo Nordisk CEO Mike Doustdar ‌said ​on Monday as many as ‌1.5 million patients in the U.S. may be using ​compounded

Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs  Reuters

IJMS, Vol. 27, Pages 759: A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms International Journal

A recent review found that many people taking GLP-1 drugs receive little or no meaningful nutrition advice

Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH

GLP-1 has become a popular buzzword in the weight-loss community — but now some are touting “GLP-3s,” claiming they are taking obesity medications to the

Amazon Pharmacy began offering Novo Nordisk’s Wegovy weight-loss pill, a move likely to intensify the drug’s impact on waistlines, grocery bills, and the food industry

Graig Suvannavejh, Biotech and Biopharma Analyst at Mizuho Securities, says Oral GLP-1 obesity drugs and looming patent cliffs will drive big pharma into biotech M&A,

FOTOARTE: MERCA2.0 What are the consumer trends for 2026? The consumer is no longer the same as just two years ago. More demanding, more hybrid,

Can eating more fiber result in eating fewer calories by suppressing our appetite? For more on fiber, check out: • Is Fiber an Effective Anti-Inflammatory?

Discontinuing obesity medicines means the weight comes back and people lose the cardiovascular and metabolic benefits conferred by the drugs.

A Guardian investigation has uncovered evidence linking Northampton-based crypto entrepreneur Fasial Tariq to what authorities described as the world’s largest illegal weight-loss drug operation. The